Insmed Incorporated (BST:IM8N)

Market Cap	20.08B +73.2%
Revenue (ttm)	710.81M +115.1%
Net Income	-1.03B
EPS	-4.95
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	46
Open	90.75
Previous Close	91.96
Day's Range	90.72 - 94.27
52-Week Range	58.00 - 184.00
Beta	n/a
RSI	33.56
Earnings Date	May 7, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 1,664
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: IM8N

Financial Performance

In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.

Financial numbers in USD